Table 1.
Baseline demographic and clinical data of the cohort.
| Characteristics | Total number of patients (n = 391) | ASUC (n = 106) | Chronic activity (n = 274) |
|---|---|---|---|
| Age, y | 38 (28-47) | 38 (29-48) | 37 (28-46) |
| Male | 208 (53.2) | 45 (42.5) | 156 (56.9) |
| pMayo | 7 (5-8) | 7 (5-8) | 6 (5-8) |
| eMayo | 3 (2-3) | 3 (3-3) | 3 (2-5) |
| CRP, mg/L | 19.3 ± 26.6 | 35.3 ± 36.82 | 13.5 ± 18.72 |
| Fecal calprotectin, µg/g | 1559.7 ± 1345.9 | 2046.5 ± 1282.7 | 1361.9 ± 1351.8 |
| Disease duration, y | 7 (4-12) | 8 (5-12) | 7 (3-12) |
| Follow-up period, wk | 26 (14-52) | 26 (14-52) | 39 (14-52) |
| Disease extensiona | |||
| Proctitis | 10 (2.6) | 3 (2.8) | 7 (2.6) |
| Left-sided colitis | 125 (32.7) | 34 (32.1) | 90 (32.8) |
| Pancolitis | 247 (64.7) | 69 (65.1) | 177 (64.6) |
| Previous colectomy + IPAA | 9 (2.3) | — | — |
| Follow-up period, wk | 26 (14-52) | 26 (14-52) | 39 (17-52) |
| Baseline concomitant treatment | |||
| 5-ASA | 206 (52.6) | 55 (51.9) | 148 (54.0) |
| Budesonide-MMX | 58 (14.8) | 20 (18.9) | 36 (13.1) |
| Azathioprine | 17 (4.3) | 5 (4.7) | 11 (4.0) |
| Methotrexate | 7 (1.8) | 2 (1.9) | 5 (1.8) |
| Cyclosporine | 6 (1.5) | 1 (0.9) | 5 (1.8) |
| Prednisolone/methylprednisolone | 179 (45.7) | 52 (49.1) | 123 (44.9) |
| Previous biologic treatments | |||
| IFX | 293 (74.9) | 74 (69.8) | 209 (76.3) |
| ADA | 153 (39.1) | 37 (34.9) | 109 (39.8) |
| GOL | 3 (0.8) | 1 (0.9) | 2 (0.7) |
| VDZ | 251 (64.2) | 64 (60.4) | 179 (65.3) |
| UST | 25 (6.4) | 9 (8.5) | 13 (4.7) |
| Therapeutic line | |||
| Biologic naive | 46 (11.8) | 21 (19.8) | 25 (9.1) |
| Second line | 89 (22.8) | 22 (20.8) | 65 (23.7) |
| Third line | 147 (37.6) | 31 (29.2) | 113 (41.2) |
| Fourth line | 97 (24.8) | 28 (26.4) | 65 (23.7) |
| Fifth line | 12 (3.1) | 4 (3.8) | 6 (2.2) |
| Extraintestinal manifestation | 85 (21.7) | 22 (20.8) | 63 (23.0) |
| Arthritis | 57 (14.6) | 15 (14.2) | 40 (14.6) |
| Erythema nodosum/pyoderma gangrenosum | 7 (1.8) | 1 (0.9) | 4 (1.5) |
| Uveitis | 2 (0.5) | 1 (0.9) | 1 (0.4) |
| PSC | 16 (4.1) | 1 (0.9) | 13 (4.7) |
Values are median (interquartile range), n (%), or mean ± SD.
Abbreviations: ADA, adalimumab; ASUC, acute severe ulcerative colitis; CRP, C-reactive protein; eMayo, Mayo endoscopic score; GOL, golimumab; IFX, infliximab; IPAA, ileal pouch–anal anastomosis; pMayo, partial Mayo score; PSC, primary sclerosing cholangitis; UST, ustekinumab; VDZ, vedolizumab; 5-ASA, 5-acetylsalicylic acid.
aMontreal classification.